NCT03935282 2026-04-15AH-HAWake Forest University Health SciencesPhase NA Completed645 enrolled 43 charts
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT04851119 2026-02-24Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsChildren's Oncology GroupPhase 1/2 Recruiting147 enrolled